文献速递心血管泌尿生殖CT

CT推导的心肌细胞外容积预测前列腺癌患者主要不良心血管事件

CT derived myocardial extracellular volume predict major adverse cardiovascular events in patients with prostate cancer.
PubMed 文献 · Eur J Radiol · 2025-08-18

回顾性纳入2014年12月1日至2020年3月31日接受雄激素剥夺治疗的前列腺癌患者180例,其中44例发生主要不良心血管事件(MACE)。胸部增强CT推导的心肌细胞外容积(ECV)在ADT后3个月较基线显著升高,12个月达峰;MACE(+)组各随访点ECV均高于MACE(-)组,ADT后3、6、9个月较高ECV与MACE风险增加相关(校正HR分别为2.695、3.670、4.450)。

要点

  • ADT后3个月心肌ECV较基线显著升高,12个月达峰值。
  • MACE(+)组各随访点心肌ECV均高于MACE(-)组。
  • ADT后3、6、9个月较高ECV与MACE风险增加相关,校正HR最高4.450。

核心结论

  • 胸部增强CT推导的心肌ECV可用于动态监测前列腺癌ADT患者的 cardiotoxicity 并预测MACE。

研究设计与样本

  • 回顾性研究,纳入2014年12月1日至2020年3月31日接受ADT的前列腺癌患者180例,于ADT前及ADT开始后约3、6、9、12个月行胸部增强CT获取心肌ECV。

诊断标准与关键数值

  • ADT后3个月心肌ECV显著高于基线,12个月达峰值。
  • ADT后3、6、9个月较高ECV与MACE风险增加相关,校正HR分别为2.695、3.670、4.450。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Prostate cancer (PCa) patients with androgen deprivation therapy (ADT) are at high risk for cardiotoxicity and major adverse cardiovascular events (MACE). It is unclear whether the myocardial extracellular volume (ECV) derived from chest contrast-enhanced CT (CECT) can detect cardiotoxicity and predict MACE in these patients. This work aimed to assess the value of chest CECT derived myocardial ECV for detecting cardiotoxicity and the association of ECV with MACE in PCa patients receiving ADT.

METHODS: PCa patients with ADT between December 1, 2014 and March 31, 2020 were retrospectively included. Chest CECT derived myocardial ECV was obtained before ADT and approximately 3, 6, 9, and 12 months after ADT initiation. The differences in myocardial ECV between the MACE (+) and MACE (-) groups were analyzed by Student's t-test, and the association between myocardial ECV and MACE was analyzed using a Cox proportional hazards model.

RESULTS: In total, 180 patients were included, of whom 44 patients developed MACE. Myocardial ECV was significantly higher after 3 months of ADT than at baseline and peaked after 12 months of ADT. Moreover, the myocardial ECV of the MACE (+) group was higher than that of the MACE (-) group at each follow-up visit. A higher ECV at 3, 6, and 9 months after ADT was associated with an increased risk for MACE (adjusted hazard ratios were 2.695, 3.670, and 4.450, respectively).

CONCLUSION: Myocardial ECV derived from chest CECT can be used to dynamically monitor cardiotoxicity and predict MACE in patients with PCa receiving ADT.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang X, Shen H, Xu Q, et al. CT derived myocardial extracellular volume predict major adverse cardiovascular events in patients with prostate cancer. Eur J Radiol. 2025. PMID: 40848521. doi:10.1016/j.ejrad.2025.112371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。